ISO supply High Pure 99% Relugolix Raw Powder CAS 737789-87-6 TAK-385 phamaceutical grade
TDS 5 Inquiries
737789-87-6
Pharmaceutical Grade
99%
China
HNB-BIOTECH
25kg/carton drum; 1kg/aluminium foil bag
2026-08-02
Ivermectin,Active pharmaceutical ingredients,Cosmetics material,Chemical intermediate,Nootropic,Food additive
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferenceRelugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under the brand name Orgovyx, for the treatment of advanced prostate cancer. Relugolix has also been studied in the symptomatic treatment of endometriosis. Relugolix is the first (and currently only) orally-administered GnRH receptor antagonist approved for the treatment of prostate cancer - similar therapies such as [degarelix] require subcutaneous administration - and therefore provides a less burdensome therapeutic option for patients who might otherwise require clinic visits for administration by healthcare professionals. In addition to its relative ease-of-use, relugolix was shown to be superior in the depression of testosterone levels when compared to [leuprolide], another androgen deprivation therapy used in the treatment of prostate cancer.|Relugolix is a Gonadotropin Releasing Hormone Receptor Antagonist. The mechanism of action of relugolix is as a Gonadotropin Releasing Hormone Receptor Antagonist, and Cytochrome P450 3A Inducer, and Cytochrome P450 2B6 Inducer, and Breast Cancer Resistance Protein Inhibitor, and P-Glycoprotein Inhibitor. The physiologic effect of relugolix is by means of Decreased GnRH Secretion.|Relugolix is an orally available, non-peptide gonadotropin-releasing hormone (GnRH or luteinizing hormone-releasing hormone (LHRH)) antagonist, with potential antineoplastic activity. Relugolix competitively binds to and blocks the GnRH receptor in the anterior pituitary gland, which both prevents GnRH binding to the GnRH receptor and inhibits the secretion and release of both luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone from Leydig cells in the testes. Since testosterone is required to sustain prostate growth, reducing testosterone levels may inhibit hormone-dependent prostate cancer cell proliferation.
Relugolix (TAK-385) is a potent, orally active, nonpeptidic gonadotropin-releasing hormone (GnRH) antagonist. It possesses high affinity and potent antagonistic activity for human receptor (binding IC50=0.33 nM) and monkey receptor (IC50=0.32 nM) compared with TAK-013 (HY-100209). Relugolix is used for the study of sex-hormone-dependent diseases, such as including endometriosis, uterine fibroids and prostate cancer et al.CertificatesBasic Info-
Product Name:
Relugolix
Other Name:Relugolix;Altropane;TKA-385 Relugolix;1-[4-[1-[(2,6-difluorophenyl)methyl]-5-(dimethylaminomethyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-6-thieno[4,5-e]pyrimidinyl]phenyl]-3-methoxyurea;Relugolix TAK-385;TAK-385,Relugolix;CS-2851;TAK-385;TAK 385;TAK385
CAS No.:737789-87-6
Molecular Formula:C29H27F2N7O5S
InChIKeys:AOMXMOCNKJTRQP-UHFFFAOYSA-N
Molecular Weight:623.63
Exact Mass:623.63
EC Number:237-099-7
UNII:P76B05O5V6
DSSTox ID:DTXSID40224167
NCI Thesaurus Code:C114498
Color/Form:White to off-white
ATC Code:H01CC54
Categories:
Characteristics-
Density:
1.442±0.06 g/cm3(Predicted)
Melting Point:228 °C (decomp)(Solv: ethyl acetate (141-78-6); tetrahydrofuran (109-99-9))
PKA:13.17±0.70(Predicted)
Critical Temperature & Pressure:Store at -20°C
Hazard IdentificationClassification of the substance or mixture
no data available
GHS label elements, including precautionary statements
Pictogram(s) no data available Signal word no data available
Hazard statement(s) no data available
Precautionary statement(s) Prevention no data available
Response no data available
Storage no data available
Disposal no data available
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
Ivermectin,Active pharmaceutical ingredients,Cosmetics material,Chemical intermediate,Nootropic,Food additive
-
Location:
6 floor Baoyilongji Building B Weiyang Area, Fengcheng 8 Road, Xi'an city, Shaanxi, 710000, China
-
Payment Terms:
L/C,TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
7
-
Total Annual Revenue:
$5 million-$10 million
-
Total Employees:
51-100
-
Year of Establishment:
2017
-
Certifications:
ISO,ISO
-
-
Inquiry History5 Inquiries
Country Product Purchase Quantity Date Posted 
United States
99% Pharmacy Grade Relugolix
100 G Nov 30, 2025 
Greece
Relugolix tablets
120 MG Nov 14, 2025 
Bangladesh
RELUGOLIX
1 20' Fcl Dec 12, 2025
Greece
Relugolix tablets
120 MG Nov 14, 2025
United States
Relugolix
10 G Sep 15, 2025 Post an enquiry for this product
